Small molecule dual neurotrophin receptor ligand to treat tauopathy

Active Grant Awarded

Award ID
R21AG093414
Recipient
Awarding agency
Obligated
$424,961

Award facts

Assistance listing
93.866 Aging Research
Completion date 10% complete
Place of performance
Palo Alto, CA 94304, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Institute on Aging awarded The Leland Stanford Junior University $424,961 on September 9, 2026, under the Aging Research program (CFDA 93.866), Grant R21AG093414. The award funds research to determine whether a small molecule dual ligand targeting the TrkB and TrkC neurotrophin receptors inhibits the pathophysiological mechanisms underlying tauopathies, including Alzheimer's disease and other related dementias. The approach engages upstream TrkB/TrkC signaling to counter multiple degenerative processes, namely tau post-translational modification and aggregation, synaptic degradation, and neuroinflammation. The application is a resubmission under the NIA Research on Current Topics in Alzheimer's Disease and Its Related Dementias announcement (R21; PAR-25-331), previously submitted to expired PAR-22-032. The award's ultimate completion date is August 31, 2028, and performance takes place in Palo Alto, California 94304. The program's purpose is to support biomedical and behavioral research and training in aging, with particular emphasis on preventing and treating Alzheimer's disease and its related dementias.

Description

Abstract
This application titled "a small molecule dual neurotrophin receptor ligand to treat tauopathy" is a resubmission in response to the NIA research on current topics in alzheimer's disease and its related dementias program announcement (R21; PAR-25-331; previously submitted to expired PAR-22-032). We will determine if a small molecule ligand targeted to the trkb and trkc neurotrophin receptors will inhibit fundamental pathophysiological mechanisms underlying tauopathies including ad and other related dementias (ADRD). Tauopathies are diseases characterized by cognitive deficits and involve pathological changes to the TAU protein. Multiple and diverse processes contribute to tauopathy-related degeneration, including TAU post-translational modifications and aggregation, synaptic degradation, and neuroinflammation. Most studies investigating tauopathy therapies target a single mechanism and although some are successful in preclinical studies, when proceeding to clinical trials, efficacy is unreliable or unattainable. Therapeutic strategies that impact several degenerative mechanisms may be more successful and can be achieved by engaging upstream targets that favorably modulate multiple and diverse downstream pathological molecular processes. Our laboratory has adopted this approach using novel, small molecule ligands for trkb and trkc, which preferentially bind the neurotrophins, bdnf and NT-3, respectively, to promote cell survival and synaptic integrity and plasticity. Trkb/C signaling pathways highly overlap the degenerative molecular pathways underlying tauopathy, synaptic deficits, and neuroinflammation. Thus, upregulating trkb/C signaling may counteract degenerative signaling to offset TAU-related degeneration. This approach has the potential for synergistic intracellular signaling, as is known to occur with TRK receptors, and combatting multi-faceted pathological mechanisms seen in adrds. Our pilot and published studies with trkb/C ligands showed that they have neurotrophic effects similar to bdnf and NT-3 and that they reduce TAU pathology in cholinergic neurons and dendritic spine loss and improve synaptic plasticity in an amyloid mouse model of ad. The proposed study aims to assess the effects of a novel, orally bioavailable, small molecule ligand of trkb and trkc, called BD10-3, against accumulation of pathological TAU species and neurodegeneration in a P310S mouse model of tauopathy. We also plan to identify tauopathy-related biofluid markers that can track the effects of BD10-3 by examining disease progression biomarkers already used for human trials. Combining a multi-target therapeutic approach with the identification of minimally invasive, translatable biomarkers that can track treatment response will increase probability of successful translation from mouse to human efficacy. If this orally bioavailable, patented ligand is effective against TAU-related degeneration, these findings would support trkb/trkc as an entirely novel therapeutic target for tauopathies and would provide the basis for comprehensive pre-IND studies and support the design of a proof-of-concept clinical trial.

Quick answers

Who received award R21AG093414?

R21AG093414 was awarded to The Leland Stanford Junior University by National Institute on Aging (National Institutes of Health) on September 9, 2026.

How much is award R21AG093414 worth?

$424,961 has been obligated on R21AG093414.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award